Dactinomycin is indicated for the treatment of multiple types of cancer including bone, testicular, kidney and muscle cancers. Dactinomycin is classified as an antibiotic but is not used as an antimicrobial agent. Dactinomycin is considered to be cell cycle–phase nonspecific. Its antineoplastic action may involve binding to DNA by intercalation between base pairs and inhibition of DNAdependent RNA synthesis. Has some bacteriostatic activity on gram-positive and on gramnegative bacteria and on some fungi. Also has some immunosuppressant activity.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Dactinomycin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.